Morning After The Mega-Rally, Lilly's COVID-19 Antibody Treatment Gets FDA Emergency Approval, And An Exclusive With McDonald's CEO
Carl Quintanilla, Jim Cramer and David Faber discussed what's ahead for stocks one day after the Dow, S&P 500 and Nasdaq each surged to record intraday highs. They explored the concept of buying value and selling growth -- and which stocks went from "cheap to overvalued" during Monday's rally. The anchors also reacted to what Eli Lilly CEO David Ricks told CNBC after the FDA authorized the company's COVID-19 antibody treatment for emergency use. In a CNBC Exclusive, McDonald's CEO Chris Kempczinski told Carl what Monday's news about Pfizer's COVID-19 vaccine candidate could mean for the fast-food giant. He also discussed the company's forthcoming plant-based burger called the "McPlant" and why he believes such products are here to stay.
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Carl Quintanilla, Jim Cramer and David Faber discussed what's ahead for stocks one day after the Dow, S&P 500 and Nasdaq each surged to record intraday highs. They explored the concept of buying value and selling growth -- and which stocks
went from "cheap to overvalued" during Monday's rally. The anchors also reacted to what Eli Lilly CEO David Ricks told CNBC after the FDA authorized the company's COVID-19 antibody treatment for emergency use.
In a CNBC Exclusive, McDonald's CEO Chris Kempczinski told Carl what Monday's news about Pfizer's COVID-19 vaccine candidate could mean for the fast-food giant. He also discussed the company's forthcoming plant-based burger called the "McPlant" and why he believes such products are here to stay.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.